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In recent years, our understanding of the genetic architec-
ture of schizophrenia, a phrase which denotes the num-
bers of risk variants, their frequencies and effect sizes, has 
been transformed. This has come about through advances 
in technology that have allowed almost the entire human 
genome to be simultaneously interrogated for the pres-
ence of disease-associated genetic variation and allows 
this to be performed in sample sizes powered for a realis-
tic possibility of success. Another development has been 
the emergence of international consortia willing to share 
raw data and their coalescence into super-consortia to 
achieve sample sizes and bodies of clinical and analytic 
expertise that was unimaginable a decade ago. These 
innovations have driven the emergence of statistically 
robust and replicable genetic findings in schizophrenia, 
and a rapid escalation in the number of those findings 
over the last 5 years.
The latest example comes from the Schizophrenia 
Working Group of the Psychiatric Genomics Consortium 
(PGC-SCZ) which, at the time of publication, included 
contributions from around 37 000 individuals with schizo-
phrenia, 302 investigators, 35 countries, and 4 continents.1 
In their recent paper, published in Nature in July 2014, 
the PGC-SCZ group report 128 statistically independent 
genetic associations, implicating a minimum of 108 con-
servatively defined schizophrenia-associated genetic loci.1
Of the identified loci, 83 have not been previously 
robustly supported as playing a role in schizophrenia, 
but it is also important to note the findings are consis-
tent with previous literature; 25 loci that had previously 
been reported as associated with schizophrenia in large 
samples were again supported in this much larger analy-
sis, confirming that the use of large samples and stringent 
statistical cut-offs results in reproducible findings. The 
availability of so many robustly supported findings offers 
immense opportunities for investigating and advancing 
our understanding of etiology.
Large numbers of alleles across the Frequency 
Spectrum
While each individual variant themselves have a small effect 
size (less than 1.4), it has been estimated that common 
variation as a whole accounts for around a third to half  
of the genetic variance in schizophrenia2,3 though this may 
turn out to be an underestimate when heterogeneity and 
interaction effects are taken into account. Nevertheless, 
rare variants also play a role. This has been well established 
for around 20  years with respect to small deletions and 
duplications known as copy number variants (CNVs)4,5 
but systematic surveys for other forms of rare genetic vari-
ation have had to await the development of high capacity 
next generation sequencing technology. These studies, par-
ticularly the larger ones,6,7 have been commented on in a 
recent review in the journal8 and will not be considered in 
detail here. However, like the early genome-wide associa-
tion studies (GWASs),2,9 rather than striking evidence for 
individual susceptibility genes, the recent sequencing stud-
ies provided evidence that many loci contribute to risk and 
for enrichment of rare mutations in certain gene sets. This 
strongly suggests that, as we have seen for GWAS, better 
powered studies will implicate specific genes.10,11
The evidence that risk variants for schizophrenia occur 
across the range of allele frequencies is compelling. As 
noted above, the contribution to risk of schizophrenia 
arising from the aggregate effect of common variants is 
not trivial, but even a single common variant can have 
a similar effect on the variance in the population as rare 
variants with larger effects simply because they occur 
much more frequently in the population.12 This suggests 
that in order to understand genetic risk mechanisms 
we will need to explore all parts of the allele frequency 
spectrum. Moreover, it seems likely that advantages may 
accrue from a combined approach to gene identification 
as the PGC-SCZ study pointed to an overlap between 
genes in schizophrenia GWAS regions and those with de 
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novo mutations. This suggests that a combination of the 
superior power of GWAS (via sample size) and the supe-
rior precision of sequencing with respect to gene identity 
might on the one hand be usefully harnessed to identify 
likely causal genes within GWAS-associated loci and on 
the other to enhance the power of sequencing by provid-
ing targets with enhanced prior probability.
Genetic associations to Biological Mechanisms
The identity of individual associations, and patterns of 
enrichment of various types of associations and disease-
linked mutations are beginning to shed light on areas of 
biology that are likely relevant to schizophrenia, although 
we stress detailed mechanistic conclusions will require 
other types of research, and that the associations at each 
locus have not yet been firmly linked to specific genes. 
Nevertheless, it is notable that within the schizophrenia-
associated loci are multiple genes involved in synaptic 
function and plasticity, particularly genes involved in 
glutamatergic neurotransmission (GRM3, GRIN2A, 
GRIA1, and SLC38A7) and neuronal calcium signaling 
(CACNA1C, CACNB2, CAMKK2, CACNA1I, NRGN, 
and RIMS1). DRD2, which a priori is possibly the stron-
gest of all conceivable candidate genes for schizophrenia 
based on function, is also associated with the disorder.
Given that most of the common variant associations do 
not appear to result from DNA changes that affect pro-
tein sequence, it is presumed, with some evidence,13 that 
they exert their effects through influencing gene expres-
sion. Investigating this hypothesis further, the PGC-SCZ 
group sought to determine if  schizophrenia-associated 
common variants are concentrated in regulatory ele-
ments marked as activating gene expression in particular 
tissues or cell lines. Importantly, though largely as pre-
dicted, associations were enriched in these regulatory ele-
ments in various brain tissues and in genes showing high 
expression in neurons/interneurons. A much more novel 
and potentially important finding was they were also 
enriched in these regulatory elements in the immune sys-
tem, particularly B-lymphocyte cell lineages. This finding 
is intriguing as it provides some genetic, and therefore 
etiological, support for the general hypothesis that 
immune dysregulation plays a role in the development of 
schizophrenia.14 However, we need to move beyond gen-
eral enrichment analyses to identify specific causal vari-
ants in specific regulatory elements, understand which 
genes/proteins are affected by those regulatory elements, 
and show how genetic variation directly affects immune 
but not neuronal function, before the immune hypoth-
esis of schizophrenia can be considered to be genetically 
confirmed.
The limited network analyses conducted by the PGC-
SCZ did not identify any generically annotated biologi-
cal pathways that were enriched for associations. This 
may reflect the restricted analyses presented, and a more 
thorough evaluation of the data is underway. But it may 
also reflect either high polygenicity and/or limitations in 
the quality and availability of data upon which to base 
these bioinformatic-driven analyses. Not only are the 
functions of many proteins unknown, but even less well 
documented are the elements that regulate the expres-
sion and processing of protein isoforms in specific cellu-
lar, developmental, and physiological contexts especially 
in the brain. Proteomic studies in particular lack the 
comprehensive scale of transcriptomic studies and are 
currently limited to targeted approaches. Interestingly, 
in PGC-SCZ, support was found for one of the most 
consistently implicated gene sets in schizophrenia, a set 
comprised of brain-expressed genes that interact with the 
Fragile X mental retardation (FMRP) protein.3,6,7,15 While 
the biological implications of this are not yet understood, 
it is likely that improving knowledge of the protein inter-
actome and of the constituent members of sets of pro-
teins involved in brain function will improve our ability 
to move from patterns of association to pathogenesis. 
This is likely to require more extensive experimental vali-
dation, and iterative refinement, of bioinformatics tools. 
For example, experimental studies reveal little overlap 
between genes predicted to be targets of microRNA-137, 
whose encoding gene lies within a schizophrenia-asso-
ciated locus, and those whose expression is affected by 
knockdown or overexpression of the microRNA16 dem-
onstrating that experimental validation of bioinformatics 
predictions is essential.
Targets of FMRP are not the only consistently impli-
cated gene set in schizophrenia. Both GWAS1,3 and exome 
sequencing7 points to the involvement of multiple calcium 
channels and multiple genes involved in calcium signal-
ing, a process also implicated in bipolar disorder.17,18 
Proteins affiliated with the N-methyl-d-aspartate receptor 
and the activity-regulated cytoskeleton-associated protein 
have been implicated by CNVs analysis19 and by exome 
sequencing,6,7,20 while as noted above, GRIN2A and mul-
tiple proteins related to glutamatergic signaling are asso-
ciated with the disorder in the recent GWAS.1 These gene 
sets plausibly converge at the functional level of synap-
tic plasticity and remodeling,6,21 although this hypothesis 
requires testing through mechanistic experimental studies.
The complexity and inaccessibility of human brain tis-
sue has made it challenging to understand basic disease 
mechanisms and to translate genetic findings into biol-
ogy. Discussed more fully in a recent review,8 a synthesis 
of gene discovery with recent advancements in stem cell 
technology and genome engineering mean that an excit-
ing avenue of research has been opened for psychiatry. 
This could be either through patient-derived induced 
pluripotent stem cells22 or through manipulations of 
cell lines by emerging gene engineering technologies.23,24 
Further discussion of these developing areas is outside 
the scope of the current article but have been discussed 
elsewhere.25–33
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pleiotropy
Pleiotropy occurs when one gene or genetic variant 
contributes to multiple phenotypes, a phenomenon fast 
becoming a characteristic of identified genetic risk factors 
for neuropsychiatric disorders. There is already evidence 
for extensive sharing of common genetic risk variants 
between schizophrenia, bipolar disorder major depres-
sive disorder, and attention deficit hyperactivity disorder 
(ADHD)17,34,35 though the evidence for ADHD is some-
what less consistent than that for the other phenotypes. 
The high genetic correlation is not explained by diagnos-
tic misclassification,36 and instead points to considerable 
genetic pleiotropy in terms of these categorically defined 
diagnoses. The same is true for rare genetic risk factors 
for schizophrenia. It has been clear for several years that 
the same CNVs that confer risk for schizophrenia also 
do so for neurodevelopmental disorders including autism 
spectrum disorders (ASD), intellectual disability, ADHD, 
and epilepsy.4,5,37,38 Given most of these CNVs affect mul-
tiple genes, it could conceivably be argued that different 
genes were involved in each phenotype, but a recent anal-
ysis of point mutations supports the view that sharing of 
risk occurs at the level of genes and types of mutation.6 
Moreover, the PGC-SCZ study found overlap between 
the genes in schizophrenia GWAS regions and those with 
de novo mutations in intellectual disability and ASD pro-
viding further support for overlapping genetic risk, and 
presumably pathophysiology.
The extent of pleiotropy may be surprising, but it is 
consistent with other disciplines which generally show 
high rates of comorbidity and lack of specificity in disease 
associations. Pleiotropy can also facilitate understanding 
of disease mechanisms by identifying novel intermedi-
ate phenotypes on the causal chain. For example, many 
risk factors for type 2 diabetes are pleiotropic for body 
mass and are likely to mediate their effects on the former 
through the latter. Of course in type 2 diabetes, there was 
a strong hypothesized link with body mass, and exploiting 
pleiotropy is not going to be quite so simple in psychiatry. 
Rather, finding pleiotropic links may require deep, and 
largely speculative, mass phenotyping. Deep phenotyping 
refers to the collection of large amounts of information 
on individuals beyond categorical diagnostic status, eg, 
cognitive and neuroimaging data, or given recent findings 
(see above) immune function. It is early days with respect 
to this type of work, but promising results have already 
been demonstrated for the first GWAS-identified schizo-
phrenia risk gene, ZNF804A,9 which have been associ-
ated with cognition, clinical subdimensions, and brain 
phenotypes.39–42 Small samples limit the robustness of the 
conclusions that have emerged so far from this sort of 
research.
Exploiting pleiotropy is likely to require very large 
cohorts, although much smaller samples ascertained for 
the same relatively high penetrance mutation, eg, a CNV, 
are also likely to be highly informative. The considerable 
genetic overlap between disorders also suggests it will be 
important that much of this work should be undertaken 
across current diagnostic boundaries (and also include 
unaffected individuals given we all carry large numbers of 
common risk alleles) in order to characterize the impact 
of genetic variants.
From Genetics to Treatment
Antipsychotics are only partly effective for the positive 
symptoms of schizophrenia and do little to alleviate the 
negative symptoms or cognitive deficits. No novel class 
of drug for schizophrenia has emerged since the 1960s,43 
presumably due to the limited understanding and insight 
into the molecular underpinnings of schizophrenia. It is 
therefore some cause for optimism that the recent PGC-
SCZ publication implicates genetic variants at the locus 
that contains DRD2, the gene that encodes the D2 dopa-
mine receptor, the target of all known effective antipsy-
chotics. The association of genetic variants at this gene 
can be seen as a “proof of principle” finding in reverse, 
supporting the hypothesis that pharmacological manipu-
lation of proteins highlighted by common variants can 
have substantial therapeutic effects regardless of the fact 
that the genetic effect size on risk is meagre.44 It also sug-
gests that other loci implicated by GWAS harbor the 
potential to guide effective drug discovery for schizophre-
nia, although we need better knowledge of the actual risk 
variants, and the proximal and distal functional conse-
quences of those variants in the pathway to disease.
Furthermore, each gene implicated in the develop-
ment of schizophrenia does not work independently. If  
the gene itself  is an unsuitable drug target, there is the 
potential for manipulation via interacting proteins or 
other members participating in the same biological path-
way. Therefore, it is important to fully characterize these 
risk genes and the cellular process, pathways, and pheno-
types which they regulate. Translating just one associated 
locus into an effective treatment for schizophrenia would 
amply justify the contribution made by tens of thousands 
of patients with the disorder that have made the recent 
genetic advances possible, and the investments of effort 
and resource by researchers and funding bodies, govern-
mental and charitable.
conclusions
The recent PGC-SCZ publication is a landmark in the 
process of identifying genetic risk variants for schizophre-
nia, but it is not one that indicates the end of the journey. 
As sample sizes and power increases, and with the addi-
tional detail provided by sequencing, discovery is likely to 
accelerate. However, even now, the genetic findings pro-
vide the basis for a wealth of research, from molecular and 
cellular investigations through to defining novel clinical 
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classifications. It is too early to know the implications for 
new treatments, although some of the associations may 
immediately inspire potential therapeutic targets. What 
would seem inevitable is that if  as yet undiscovered treat-
ments for the disorder are possible, and it seems unlikely 
that the only effective treatment has already been dis-
covered, the opportunities for better understanding of 
pathogenesis that flow from the genetic data must surely 
accelerate their discovery. For this to happen, scientists 
of many disciplines must move away from the comfort 
of some of the “old favourites,” for which the evidence is 
much less secure and devote their energies and intellect in 
pursuit of the new findings that are well grounded in evi-
dence. Looking beyond schizophrenia, the findings defini-
tively demonstrate the power of genetics can be harnessed 
for psychiatric phenotypes despite their presumed high 
heterogeneity, the absence of tests to validate diagnosis, 
and uncertain biological validity.
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